Publications by authors named "Markus Perl"

Claim this Profile
G
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy.
Stefan Enssle, Anna Sax, Peter May, Nadia El Khawanky, Nardine Soliman, Markus Perl

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microbial metabolite desaminotyrosine protects against graft-versus-host disease via mTORC1 and STING-dependent intestinal regeneration.
Sascha Göttert, Erik Thiele Orberg, Kaiji Fan, Paul Heinrich, Diana M Matthe, Markus Perl

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T cell therapy for relapsed/refractory posttransplant lymphoproliferative disorder.
Helena Hansmann, Chiara Henkel, Matthias A Fante, Dennis C Harrer, Stefanie Heidemanns, Markus Perl

Am J Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.
Leonard Knoedler, Konstantin Herfeld, Daniel A Schaefer, Fortunay Diatta, James Clune, Markus Perl

Cell Rep Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbiota-derived metabolites: Key modulators of cancer immunotherapies.
Markus Perl, Matthias A Fante, Konstantin Herfeld, Julian N Scherer, Hendrik Poeck

Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.
Silke Heidenreich, Katharina Egger-Heidrich, Jörg P Halter, Lasse Jost, Friedrich Stölzel, Markus Perl

Bone Marrow Transplant· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells.
Sarah Staudt, Fabian Nikolka, Markus Perl, Julia Franz, Noemie Leblay

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.
Markus Perl, Konstantin Herfeld, Dennis C Harrer, Matthias Höpting, Marina Schweiger

Haematologica· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From standard therapies to monoclonal antibodies and immune checkpoint inhibitors - an update for reconstructive surgeons on common oncological cases.
Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Markus Perl

Front Immunol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Jana Doering, Markus Perl, Daniela Weber, Bernhard Banas, Christian Schulz

Transplant Cell Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.
Simon Heidegger, Florian Stritzke, Sarah Dahl, Juliane Daßler-Plenker, Laura Joachim, Markus Perl

Cell Rep Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thinking like a Lawyer-Human Rights and Their Association with the Plastic Surgeon of Today.
Leonard Knoedler, Berkin Oezdemir, Philipp Moog, Lukas Prantl, P Niclas Broer, Markus Perl

Aesthetic Plast Surg· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.
Maximilian Ehrenfeld, Anna Schrade, Tatiana Flisikowska, Markus Perl, Noah-David Hirsch

Mol Cancer Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD).
Daniel Authier, Ute Hegenbart, Fabian Pohl, Andreas Rosenwald, Stefan Kircher, Markus Perl

Leuk Lymphoma· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Colorectal Cancer Lipidome: Identification of a Robust Tumor-Specific Lipid Species Signature.
Josef Ecker, Elisa Benedetti, Alida S D Kindt, Marcus Höring, Markus Perl

Gastroenterology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS.
Johannes Hofer, Magdalena Riedl Khursigara, Markus Perl, Thomas Giner, Alejandra Rosales

Pediatr Nephrol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MALDI-2 Mass Spectrometry and Immunohistochemistry Imaging of Gb3Cer, Gb4Cer, and Further Glycosphingolipids in Human Colorectal Cancer Tissue.
Tanja Bien, Markus Perl, Andrea C Machmüller, Ulrich Nitsche, Anja Conrad

Anal Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Philipp Emanuel Geyer, Matthias Maak, Ulrich Nitsche, Markus Perl, Alexander Novotny

Mol Cancer Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis